Wachter, Rolf

[["dc.bibliographiccitation.firstpage","540"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Biomarkers"],["dc.bibliographiccitation.lastpage","550"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Baldassarri, Flavia"],["dc.contributor.author","Schwedhelm, Edzard"],["dc.contributor.author","Atzler, Dorothee"],["dc.contributor.author","Böger, Rainer H."],["dc.contributor.author","Cordts, Kathrin"],["dc.contributor.author","Haller, Bernhard"],["dc.contributor.author","Pressler, Axel"],["dc.contributor.author","Müller, Stephan"],["dc.contributor.author","Suchy, Christiane"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Duvinage, André"],["dc.date.accessioned","2020-12-10T18:15:03Z"],["dc.date.available","2020-12-10T18:15:03Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1080/1354750X.2018.1460762"],["dc.identifier.eissn","1366-5804"],["dc.identifier.issn","1354-750X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74724"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Relationship between exercise intervention and NO pathway in patients with heart failure with preserved ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1067"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","1074"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Bobenko, Anna"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Duvinage, André"],["dc.contributor.author","Schwarz, Silja"],["dc.contributor.author","Mende, Meinhard"],["dc.contributor.author","Prettin, Christiane"],["dc.contributor.author","Trippel, Tobias"],["dc.contributor.author","Lindhorst, Ruhdja"],["dc.contributor.author","Morris, Daniel"],["dc.contributor.author","Pieske-Kraigher, Elisabeth"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Pieske, Burkert"],["dc.date.accessioned","2018-04-23T11:48:12Z"],["dc.date.available","2018-04-23T11:48:12Z"],["dc.date.issued","2017"],["dc.description.abstract","Heart failure with preserved ejection fraction (HFpEF) is a common disease with high incidence and increasing prevalence. Patients suffer from functional limitation, poor health‐related quality of life, and reduced prognosis. A pilot study in a smaller group of HFpEF patients showed that structured, supervised exercise training (ET) improves maximal exercise capacity, diastolic function, and physical quality of life. However, the long‐term effects of ET on patient‐related outcomes remain unclear in HFpEF. The primary objective of the Exercise training in Diastolic Heart Failure (Ex‐DHF) trial is to investigate whether a 12 month supervised ET can improve a clinically meaningful composite outcome score in HFpEF patients. Components of the outcome score are all‐cause mortality, hospitalizations, NYHA functional class, global self‐rated health, maximal exercise capacity, and diastolic function. After undergoing baseline assessments to determine whether ET can be performed safely, 320 patients at 11 trial sites with stable HFpEF are randomized 1:1 to supervised ET in addition to usual care or to usual care alone. Patients randomized to ET perform supervised endurance/resistance ET (3 times/week at a certified training centre) for 12 months. At baseline and during follow‐up, anthropometry, echocardiography, cardiopulmonary exercise testing, and health‐related quality of life evaluation are performed. Blood samples are collected to examine various biomarkers. Overall physical activity, training sessions, and adherence are monitored and documented throughout the study using patient diaries, heart rate monitors, and accelerometers. The Ex‐DHF trial is the first multicentre trial to assess the long‐term effects of a supervised ET programme on different outcome measures in patients with HFpEF."],["dc.identifier.doi","10.1002/ejhf.862"],["dc.identifier.gro","3142337"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/13472"],["dc.language.iso","en"],["dc.notes.intern","lifescience updates Crossref Import"],["dc.notes.status","final"],["dc.relation.issn","1388-9842"],["dc.title","Exercise training in Diastolic Heart Failure (Ex-DHF): rationale and design of a multicentre, prospective, randomized, controlled, parallel group trial"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","53"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","62"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Bobenko, Anna"],["dc.contributor.author","Bartels, Inke"],["dc.contributor.author","Münch, Marlene"],["dc.contributor.author","Trippel, Tobias"],["dc.contributor.author","Lindhorst, Ruhdja"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Duvinage, André"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Tschöpe, Carsten"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2018-04-23T11:48:01Z"],["dc.date.available","2018-04-23T11:48:01Z"],["dc.date.issued","2018"],["dc.description.abstract","Aims Heart failure with preserved ejection fraction (HFpEF) remains a common condition with no pharmacological treatment. Physical activity (PA) improves symptoms and quality of life (QoL), but no clear recommendations exist on PA in HFpEF patients. We investigated the association of PA (amount/intensity) on clinical phenotype in HFpEF. Methods and results The Aldosterone in Diastolic Heart Failure trial investigated spironolactone vs. placebo in stable HFpEF patients. At baseline, all patients underwent detailed phenotypization including echocardiography, cardiopulmonary exercise testing, 6 minute walking test (6MWT), and QoL assessment (36‐item Short‐Form questionnaire). PA was assessed by a self‐report questionnaire, classified in metabolic equivalents of task (MET) and analysed with regard to exercise capacity, diastolic function, and QoL. Four hundred twenty‐two patients (52% women, age 67 ± 8 years, New York Heart Association II and III) were classified by weekly MET hours into a low (<70), middle (70–140), or high (>140) level of PA. Total PA correlated positively with 6MWT distance (r = 0.17; P = 0.002) and physical function of QoL (r = 0.10; P = 0.05), but not with peak oxygen uptake (peakVO2). In contrast, both 6MWT distance and peakVO2 were significantly higher in patients who performed high‐intensity PA for >8 h/week (P < 0.001, P = 0.02, respectively). Time of high‐intensity PA was related to higher 6MWT distance (r = 0.21, P < 0.001), peakVO2, and better physical function of QoL (both r = 0.13, P = 0.01), whereas low‐intensity PA did not show significant associations. Interestingly, PA was not related to any measure of diastolic function. Conclusions A higher amount of PA is related to higher submaximal exercise capacity and physical function of QoL. Regarding maximal exercise capacity, only high‐intensity PA showed significant association in HFpEF patients."],["dc.identifier.doi","10.1002/ehf2.12227"],["dc.identifier.gro","3142318"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/13451"],["dc.language.iso","en"],["dc.notes.intern","lifescience updates Crossref Import"],["dc.notes.status","final"],["dc.relation.issn","2055-5822"],["dc.title","Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2296"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Biomedicines"],["dc.bibliographiccitation.volume","10"],["dc.contributor.affiliation","Lechner, Katharina; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany"],["dc.contributor.affiliation","von Schacky, Clemens; 4Omegametrix, Martinsried, 82152 Munich, Germany"],["dc.contributor.affiliation","Scherr, Johannes; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany"],["dc.contributor.affiliation","Lorenz, Elke; 3Kardiologie, Deutsches Herzzentrum München, 80636 Munich, Germany"],["dc.contributor.affiliation","Bock, Matthias; 2DZHK (German Centre for Cardiovascular Research), Partner Site Munich, Munich Heart Alliance, 80336 Munich, Germany"],["dc.contributor.affiliation","Lechner, Benjamin; 6Department of Internal Medicine IV, Ludwig-Maximilians University, 80336 Munich, Germany"],["dc.contributor.affiliation","Haller, Bernhard; 7Institute of AI and Informatics in Medicine, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany"],["dc.contributor.affiliation","Krannich, Alexander; 8Charité, Universitätsmedizin Berlin, 10117 Berlin, Germany"],["dc.contributor.affiliation","Halle, Martin; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany"],["dc.contributor.affiliation","Wachter, Rolf; 9Clinic and Policlinic for Cardiology, University Hospital Leipzig, 04103 Leipzig, Germany"],["dc.contributor.affiliation","Duvinage, André; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany"],["dc.contributor.affiliation","Edelmann, Frank; 12Department of Cardiology, Charité, Universitätsmedizin Berlin, 10117 Berlin, Germany"],["dc.contributor.author","Lechner, Katharina"],["dc.contributor.author","von Schacky, Clemens"],["dc.contributor.author","Scherr, Johannes"],["dc.contributor.author","Lorenz, Elke"],["dc.contributor.author","Bock, Matthias"],["dc.contributor.author","Lechner, Benjamin"],["dc.contributor.author","Haller, Bernhard"],["dc.contributor.author","Krannich, Alexander"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Duvinage, André"],["dc.contributor.editor","Drozd, Arleta"],["dc.date.accessioned","2022-10-04T10:21:47Z"],["dc.date.available","2022-10-04T10:21:47Z"],["dc.date.issued","2022"],["dc.date.updated","2022-11-11T13:13:12Z"],["dc.description.abstract","Background: Circulating long-chain (LCSFAs) and very long-chain saturated fatty acids (VLSFAs) have been differentially linked to risk of incident heart failure (HF). In patients with heart failure with preserved ejection fraction (HFpEF), associations of blood SFA levels with patient characteristics are unknown. Methods: From the Aldo-DHF-RCT, whole blood SFAs were analyzed at baseline in n = 404 using the HS-Omega-3-Index® methodology. Patient characteristics were 67 ± 8 years, 53% female, NYHA II/III (87%/13%), ejection fraction ≥50%, E/e’ 7.1 ± 1.5; and median NT-proBNP 158 ng/L (IQR 82–298). Spearman´s correlation coefficients and linear regression analyses, using sex and age as covariates, were used to describe associations of blood SFAs with metabolic phenotype, functional capacity, cardiac function, and neurohumoral activation at baseline and after 12-month follow-up (12 mFU). Results: In line with prior data supporting a potential role of de novo lipogenesis-related LCSFAs in the development of HF, we showed that baseline blood levels of C14:0 and C16:0 were associated with cardiovascular risk factors and/or lower exercise capacity in patients with HFpEF at baseline/12 mFU. Contrarily, the three major circulating VLSFAs, lignoceric acid (C24:0), behenic acid (C22:0), and arachidic acid (C20:0), as well as the LCSFA C18:0, were broadly associated with a lower risk phenotype, particularly a lower risk lipid profile. No associations were found between cardiac function and blood SFAs. Conclusions: Blood SFAs were differentially linked to biomarkers and anthropometric markers indicative of a higher-/lower-risk cardiometabolic phenotype in HFpEF patients. Blood SFA warrant further investigation as prognostic markers in HFpEF. One Sentence Summary: In patients with HFpEF, individual circulating blood SFAs were differentially associated with cardiometabolic phenotype and aerobic capacity."],["dc.description.sponsorship","German Foundation of Heart Research"],["dc.description.sponsorship","Federal Ministry of Education and research"],["dc.identifier.doi","10.3390/biomedicines10092296"],["dc.identifier.pii","biomedicines10092296"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114500"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-600"],["dc.publisher","MDPI"],["dc.relation.eissn","2227-9059"],["dc.rights","Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."],["dc.title","Saturated Fatty Acid Blood Levels and Cardiometabolic Phenotype in Patients with HFpEF: A Secondary Analysis of the Aldo-DHF Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.contributor.author","Lechner, Katharina"],["dc.contributor.author","Scherr, Johannes"],["dc.contributor.author","Lorenz, Elke"],["dc.contributor.author","Lechner, Benjamin"],["dc.contributor.author","Haller, Bernhard"],["dc.contributor.author","Krannich, Alexander"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Duvinage, André"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2021-10-01T09:58:53Z"],["dc.date.available","2021-10-01T09:58:53Z"],["dc.date.issued","2021"],["dc.description.abstract","Abstract Objectives To evaluate associations of omega-3 fatty acid (O3-FA) blood levels with cardiometabolic risk markers, functional capacity and cardiac function/morphology in patients with heart failure with preserved ejection fraction (HFpEF). Background O3-FA have been linked to reduced risk for HF and associated phenotypic traits in experimental/clinical studies. Methods This is a cross-sectional analysis of data from the Aldo-DHF-RCT. From 422 patients, the omega-3-index (O3I = EPA + DHA) was analyzed at baseline in n  = 404 using the HS-Omega-3-Index ® methodology. Patient characteristics were; 67 ± 8 years, 53% female, NYHA II/III (87/13%), ejection fraction ≥ 50%, E / e ′ 7.1 ± 1.5; median NT-proBNP 158 ng/L (IQR 82–298). Pearson’s correlation coefficient and multiple linear regression analyses, using sex and age as covariates, were used to describe associations of the O3I with metabolic phenotype, functional capacity, echocardiographic markers for LVDF, and neurohumoral activation at baseline/12 months. Results The O3I was below (< 8%), within (8–11%), and higher (> 11%) than the target range in 374 (93%), 29 (7%), and 1 (0.2%) patients, respectively. Mean O3I was 5.7 ± 1.7%. The O3I was inversely associated with HbA1c ( r  = − 0.139, p  = 0.006), triglycerides-to-HDL-C ratio ( r  = − 0.12, p  = 0.017), triglycerides ( r  = − 0.117, p  = 0.02), non-HDL-C ( r  = − 0.101, p  = 0.044), body-mass-index ( r  = − 0.149, p  = 0.003), waist circumference ( r  = − 0.121, p  = 0.015), waist-to-height ratio ( r  = − 0.141, p  = 0.005), and positively associated with submaximal aerobic capacity ( r  = 0.113, p  = 0.023) and LVEF ( r  = 0.211, p  < 0.001) at baseline. Higher O3I at baseline was predictive of submaximal aerobic capacity ( β  = 15.614, p  < 0,001), maximal aerobic capacity ( β  = 0.399, p  = 0.005) and LVEF ( β  = 0.698, p  = 0.007) at 12 months. Conclusions Higher O3I was associated with a more favorable cardiometabolic risk profile and predictive of higher submaximal/maximal aerobic capacity and lower BMI/truncal adiposity in HFpEF patients. Graphic abstract Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients. Higher O3I was associated with a more favorable cardiometabolic risk profile and aerobic capacity (left) but did not correlate with echocardiographic markers for left ventricular diastolic function or neurohumoral activation (right). An O3I-driven intervention trial might be warranted to answer the question whether O3-FA in therapeutic doses (with the target O3I 8–11%) impact on echocardiographic markers for left ventricular diastolic function and neurohumoral activation in patients with HFpEF. This figure contains modified images from Servier Medical Art ( https://smart.servier.com ) licensed by a Creative Commons Attribution 3.0 Unported License."],["dc.description.abstract","Abstract Objectives To evaluate associations of omega-3 fatty acid (O3-FA) blood levels with cardiometabolic risk markers, functional capacity and cardiac function/morphology in patients with heart failure with preserved ejection fraction (HFpEF). Background O3-FA have been linked to reduced risk for HF and associated phenotypic traits in experimental/clinical studies. Methods This is a cross-sectional analysis of data from the Aldo-DHF-RCT. From 422 patients, the omega-3-index (O3I = EPA + DHA) was analyzed at baseline in n  = 404 using the HS-Omega-3-Index ® methodology. Patient characteristics were; 67 ± 8 years, 53% female, NYHA II/III (87/13%), ejection fraction ≥ 50%, E / e ′ 7.1 ± 1.5; median NT-proBNP 158 ng/L (IQR 82–298). Pearson’s correlation coefficient and multiple linear regression analyses, using sex and age as covariates, were used to describe associations of the O3I with metabolic phenotype, functional capacity, echocardiographic markers for LVDF, and neurohumoral activation at baseline/12 months. Results The O3I was below (< 8%), within (8–11%), and higher (> 11%) than the target range in 374 (93%), 29 (7%), and 1 (0.2%) patients, respectively. Mean O3I was 5.7 ± 1.7%. The O3I was inversely associated with HbA1c ( r  = − 0.139, p  = 0.006), triglycerides-to-HDL-C ratio ( r  = − 0.12, p  = 0.017), triglycerides ( r  = − 0.117, p  = 0.02), non-HDL-C ( r  = − 0.101, p  = 0.044), body-mass-index ( r  = − 0.149, p  = 0.003), waist circumference ( r  = − 0.121, p  = 0.015), waist-to-height ratio ( r  = − 0.141, p  = 0.005), and positively associated with submaximal aerobic capacity ( r  = 0.113, p  = 0.023) and LVEF ( r  = 0.211, p  < 0.001) at baseline. Higher O3I at baseline was predictive of submaximal aerobic capacity ( β  = 15.614, p  < 0,001), maximal aerobic capacity ( β  = 0.399, p  = 0.005) and LVEF ( β  = 0.698, p  = 0.007) at 12 months. Conclusions Higher O3I was associated with a more favorable cardiometabolic risk profile and predictive of higher submaximal/maximal aerobic capacity and lower BMI/truncal adiposity in HFpEF patients. Graphic abstract Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients. Higher O3I was associated with a more favorable cardiometabolic risk profile and aerobic capacity (left) but did not correlate with echocardiographic markers for left ventricular diastolic function or neurohumoral activation (right). An O3I-driven intervention trial might be warranted to answer the question whether O3-FA in therapeutic doses (with the target O3I 8–11%) impact on echocardiographic markers for left ventricular diastolic function and neurohumoral activation in patients with HFpEF. This figure contains modified images from Servier Medical Art ( https://smart.servier.com ) licensed by a Creative Commons Attribution 3.0 Unported License."],["dc.identifier.doi","10.1007/s00392-021-01925-9"],["dc.identifier.pii","1925"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/90166"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-469"],["dc.relation.eissn","1861-0692"],["dc.relation.issn","1861-0684"],["dc.title","Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","76"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","84"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Stahrenberg, Raoul"],["dc.contributor.author","Duvinage, André"],["dc.contributor.author","Mende, Meinhard"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","auf der Heide, Wiebke"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Binder, Lutz"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2019-07-09T11:41:22Z"],["dc.date.available","2019-07-09T11:41:22Z"],["dc.date.issued","2015"],["dc.description.abstract","Objectives and Background The aim of this study was to identify determinants of submaximal exercise capacity as measured by 6 min walking distance in patients at risk for heart failure with preserved ejection fraction (HFpEF). Methods A cross-sectional analysis from the prospective cohort programme Prevalence and Clinical Course of Diastolic Dysfunction and Heart Failure (DIAST-CHF) that included a total of 1937 patients (age, 50–85 years) with >1 risk factor (hypertension, atherosclerotic disease, diabetes mellitus, and obstructive sleep apnoea) was carried out. Besides comprehensive clinical phenotyping, standardized 6min walk test and state-of-the-art echocardiography were performed, and blood samples for biomarker assessment were obtained. Patients with an ejection fraction <50% or without evaluable exercise test were excluded from this analysis. Results One thousand three hundred eighty-seven patients fulfilled all criteria for this analysis. In the univariate analysis, 6 min walk distance was inversely related to E/e′ values (P<0.001). In the multivariate analysis, 6 min walk distance decreased significantly with age, female sex, increasing body mass index, diabetes, chronic obstructive lung disease, and peripheral artery disease. However, the association of 6 min walk distance with resting parameters of diastolic function was significantly attenuated with multivariate regression. In contrast, mid-regional pro-adrenomedullin, mid-regional pro-atrial natriuretic peptide, and N-terminal pro-B-type natriuretic peptide were independently associated with submaximal exercise capacity when added to the base model (all P<0.001). Conclusions Classical risk factors for heart failure and neuroendocrine activation are independently associated with submaximal exercise capacity, while diastolic function parameters obtained at rest were not. This observation substantiates the role of co-morbidities as relevant contributors to the clinical picture of HFpEF and the limitation of resting indices of diastolic function for diagnosing HFpEF."],["dc.identifier.doi","10.1002/ehf2.12034"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11998"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58413"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Determinants of submaximal exercise capacity in patients at risk for heart failure with preserved ejection fraction-results from the DIAST-CHF study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]